Bristol-Myers Squibb - Social Responsibility - Clinical Outcomes and Research Grants

Patient Assistance Programs

Fighting AIDS in Africa

Bristol-Myers Squibb Foundation & Corporate Philanthropy

Product Integrity

Sustainability: Our Plan for Responsible Growth

Environment, Health & Safety Policy

Medical Education Grants And Charitable Contributions

Clinical Outcomes And Research Grants

	Overview
	Virology Fellows Research Training Program

Position On Key Issues

» BMS.com Home » Social Responsibility » Clinical Outcomes and Research Grants - Program Guidance

Program Guidance

Bristol-Myers Squibb will consider support of an IST which meets the criteria as described under our Policy Statement. ISTs must be medically appropriate and scientifically valid. While BMS will consider requests for clinical research trials in all clinical and therapeutic areas, we currently give priority to proposals in the following therapeutic areas: Cardiovascular/Metabolics, Infectious Diseases, Neuroscience, Oncology, Immunology, and Virology. Bristol-Myers Squibb maintains a strict policy of not exercising any influence or control over the design of any investigator initiated clinical research trial supported by BMS.

Before you start the submission process, please be sure to have the following information available.

1. Federal Tax ID number for institution/organization (as applicable)
2. Organizational Information (demographics for investigator/sponsor institution)
3. Trial Design and Details
4. Valid E-Mail for communications
5. Pharmacy or drug distribution contact information
6. Detailed Budget
7. Study Timeline Information
8. Statistical Plan
9. Publication Plan

A copy of primary investigator’s current curriculum vitae (CV) must be submitted with the concept application.

Click Here to Begin a New Application >>

Click Here to Return to a Saved Application >>

[Top Page] [Search] [Index] [Contact] [Home]

Italicized product names are trademarks of Bristol-Myers Squibb Company or one of its divisions or subsidiaries. Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd. Erbitux is a trademark of ImClone Systems Incorporated. EMSAM is a trademark of Somerset Pharmaceuticals, Inc. Glucophage, Glucovance and Metaglip are trademarks of Merck Santé S.A.S., an associate of Merck KGaA of Darmstadt, Germany. Avapro, Avalide and Plavix are trademarks of sanofi-aventis. Sinemet CR is a trademark of Merck & Co., Inc.